TA137 Rituximab ar gyfer trin lymffoma ffoliglaidd cam III neu IV nad yw'n lymffoma Hodgkin ar ôl ailwaelu neu os nad yw'n ymateb mwyach i driniaeth: deall canllawiau (fformat MS Word)

The summary of the key recommendations of the technology appraisal on Lymphoma (follicular non-Hodgkin's) - rituximab. It is written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets or any other suitable publication.